SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-009844 to BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)

BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)
Date: Aug. 29, 2024 · CIK: 0001580063 · Accession: 0000000000-24-009844

AI Filing Summary & Sentiment

File numbers found in text: 333-281768

Date
August 29, 2024
Author
Not clearly detected
Form
UPLOAD
Company
BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)

Letter

August 29, 2024 Eric d'Esparbes Chief Financial Officer Biora Therapeutics, Inc. 4330 La Jolla Village Drive, Suite 300 San Diego, CA 92122 Re:Biora Therapeutics, Inc. Registration Statement on Form S-3 Filed August 23, 2024 File No. 333-281768 Dear Eric d'Esparbes: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Ryan Murr, Esq.

Show Raw Text
August 29, 2024
Eric d'Esparbes
Chief Financial Officer
Biora Therapeutics, Inc.
4330 La Jolla Village Drive, Suite 300
San Diego, CA 92122
Re:Biora Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 23, 2024
File No. 333-281768
Dear Eric d'Esparbes:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Ryan Murr, Esq.